Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ROS1 | P08922 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24312365 | 0.88 | PARP10 (0.40) | PARP10PARP1PARP11MAPTKDM4E | |
| SCHEMBL5546719 | 0.70 | ALDH1A1 (0.58) | PARP10PARP1PARP11MAPTKDM4E | |
| SCHEMBL19978083 | 0.70 | PARP10 (0.46) | PARP10PARP1PARP11MAPTKDM4E | |
| SCHEMBL7045045 | 0.70 | MAPT (0.39) | EGFRMAPTKDM4EALDH1A1MEN1 | |
| SCHEMBL21160781 | 0.70 | PARP10 (0.42) | PARP10PARP1PARP11MAPTKDM4E | |
| SCHEMBL10122765 | 0.66 | PARP10 (0.39) | PARP10PARP1PARP11MAPTKDM4E | |
| SCHEMBL18944161 | 0.66 | PARP10 (0.39) | PARP10PARP1PARP11MAPTKDM4E | |
| SCHEMBL7048653 | 0.66 | KDM4E (0.41) | EGFRMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL20042468 | 0.66 | KDM4E (0.41) | EGFRMAPTKDM4EALDH1A1HPGD | |
| SCHEMBL23278523 | 0.66 | MAPT (0.36) | EGFRMAPTKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732286-B2 | T5 exonuclease-based method to identify DNA topoisomerase inhibitors | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230044407-A1 | TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER | THE TRUSTEES OF DARTMOUTH COLLEGE | 2023-02-09 | — | — | US | disclosed |
| US-20230044407-A1 | TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER | THE TRUSTEES OF DARTMOUTH COLLEGE | 2023-02-09 | — | — | US | disclosed |
| US-20220170070-A1 | T5 EXONUCLEASE-BASED METHOD TO IDENTIFY DNA TOPOISOMERASE INHIBITORS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220119858-A1 | T5 EXONUCLEASE-BASED METHOD TO IDENTIFY DNA TOPOISOMERASE INHIBITORS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2022-04-21 | — | — | US | disclosed |
| US-11268129-B1 | T5 exonuclease-based method to identify DNA topoisomerase inhibitors | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2022-03-08 | — | — | US | disclosed |
| WO-2021113347-A1 | TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230044407-A1 | TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER | MYCBP, MYC, TERF2IP | PARP10 1211/4885PARP1 2412/4885EGFR 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.